Skip to main content

Generic Tabrecta Availability

Last updated on Nov 8, 2022.

Tabrecta is a brand name of capmatinib, approved by the FDA in the following formulation(s):

TABRECTA (capmatinib hydrochloride - tablet;oral)

  • Manufacturer: NOVARTIS PHARM
    Approval date: May 6, 2020
    Strength(s): EQ 150MG BASE [RLD], EQ 200MG BASE [RLD]

Has a generic version of Tabrecta been approved?

No. There is currently no therapeutically equivalent version of Tabrecta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tabrecta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,596,178

    Patent expiration dates:

    • July 22, 2035
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent 7,767,675
    Issued: August 3, 2010
    Inventor(s): Zhuo; Jincong & Xu; Meizhong & He; Chunhong & Zhang; Colin & Qian; Ding-Quan & Metcalf; Brian & Yao; Wenqing
    Assignee(s): Incyte Corporation

    The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

    Patent expiration dates:

    • November 19, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
    Patent 8,420,645
    Issued: April 16, 2013
    Assignee(s): Incyte Corporation

    The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.

    Patent expiration dates:

    • June 5, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent 8,461,330
    Issued: June 11, 2013
    Assignee(s): Incyte Corporation

    The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

    Patent expiration dates:

    • November 19, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
    Patent 8,901,123
    Issued: December 2, 2014
    Assignee(s): Incyte Corporation

    The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.

    Patent expiration dates:

    • May 20, 2029
      ✓ 
      Patent use: USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • May 6, 2025 - NEW CHEMICAL ENTITY
    • May 6, 2027 - INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.